Year | Title of the study/activity funded | Funder |
---|---|---|
2008 | Pharmacovigilance for Artemisinin-based combination treatments in Africa | World Health Organization/(WHO/TDR) |
Multi-drug resistance in malaria under combination therapy Assessment of specific markers and development of innovative, rapid and simple diagnostics (MALACTRES) | European Union (FP7) | |
Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women with Plasmodium falciparum infection | Malaria in Pregnancy (MiP) Consortium | |
A Phase II multicenter, efficacy and safety study of parenteral SAR97276A | Sanofi Aventis | |
2009 | Safe and efficacious artemisinin-based combination treatments for African pregnant women with malaria | European and Developing Countries Partnership (EDCTP) |
Efficacy of GSK Biologicals. candidate malaria vaccine (257049)against malaria disease caused by P. falciparum infection in infants and children in Africa | Malaria Vaccine Initiative (MVI) | |
Parallel group, double-blind, randomized study assessing the efficacy, safety and pharmacokinetic profile of ferroquine associated with artesunate | Sanofi aventis | |
2010 | Assessment of the Safety of Anti-malarial Drug Use During Early Pregnancy | Malaria in Pregnancy (MiP) Consortium |
Malaria risk prior to and during early pregnancy in nulliparous women receiving long-term weekly iron and folic acid supplementation | National Institute of Health (NIH) | |
Epidemiology study of malaria transmission intensity in sub-Saharan Africa | Malaria Vaccine Initiative (MVI) | |
Study of immune correlates of protection against malaria after vaccination with RTS, S/AS01E | Malaria Vaccine Initiative (MVI) | |
Multi-methods study on Clinical Trial participation and the informed consent process in vulnerable populations | Belgian cooperation | |
2011 | Site characterization as a prelude to a study of malaria elimination using a combination of malaria control strategies in the Sahel region of Burkina Faso | Malaria Capacity Development Consortium (MCDC) |
Phase III randomized, open, controlled study to evaluate the immune response to the hepatitis B antigen of the RTS,S/AS01E candidate vaccine | GlaxoSmithKline (GSK) Biologicals | |
Improved quality of diagnostic services for malaria in pregnancy | World Health Organization/(WHO/TDR) | |
2012 | Severe malaria and invasive bacterial disease among children: proportions, incidence rates and diagnostic value of Malaria Rapid Diagnostic Tests (ongoing) | Institute of Tropical Medicine (Belgium Cooperation) |
Community-based scheduled screening and treatment of malaria in pregnancy for improved maternal and infant health: a cluster-randomized trial in The Gambia, Burkina Faso and Benin | European Union (EU FP7) | |
Genomic and environmental risk factors for cardio-metabolic disease in Africans. | National Institute of Health (NIH) | |
2013 | Study of the Incidence, Reservoir and Routes of Transmission of Invasive Salmonellosis in Burkina Faso (IRTIS -BF) | Institute of tropical medicine (Belgium Cooperation) |
An open-label, single-arm study to evaluate the efficacy, safety and PK of Artemether-Lumefantrine dispersible tablet in the treatment of acute uncomplicated Plasmodium falciparum malaria in infants <5 kg body weight | Novartis | |
A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamics and safety study of a new paediatric eurartesim dispersible formulation and crushed film coated eurartesim tablet, in infant patients with Plasmodium falciparum malaria | Sigma Tau | |
Observational study to evaluate the clinical safety after introduction of the fixed-dose Artemisinin-based Combination Therapy Eurartesim® (dihydroartemisinin/piperaquine [DHA/PQP]) in public health districts in Burkina Faso, Mozambique, Ghana and Tanzania | Indepth network |